Cargando…

Long-term prognosis of parathyroid function in chronic dialysis patients after PEIT—a single-centre trial

Background. Secondary hyperparathyroidism (SHPT) is a common complication observed in long-term dialysis patients. Percutaneous ethanol injection therapy (PEIT) of parathyroid glands (PTGs) is now established in Japan as a treatment option for SHPT. In this study, to elucidate the factors influencin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Reika, Kakuta, Takatoshi, Koiwa, Fumihiko, Fukagawa, Masafumi, Saito, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421133/ https://www.ncbi.nlm.nih.gov/pubmed/25983970 http://dx.doi.org/10.1093/ndtplus/sfn084

Ejemplares similares

Indication and efficacy of PEIT in the management of secondary hyperparathyroidism
por: Koiwa, Fumihiko, et al.
Publicado: (2008)

New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients
por: Onoda, Noritaka, et al.
Publicado: (2008)

Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention
por: Kakuta, Takatoshi, et al.
Publicado: (2008)

Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review
por: Komaba, Hirotaka, et al.
Publicado: (2008)

Parathyroid hormone-producing cells exist in adipose tissues surrounding the parathyroid glands in hemodialysis patients with secondary hyperparathyroidism
por: Kakuta, Takatoshi, et al.
Publicado: (2020)

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
por: Koiwa, Fumihiko, et al.
Publicado: (2023)

Medical management after parathyroid intervention
por: Tanaka, Motoko, et al.
Publicado: (2008)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open‐label, multicentre, 12‐week phase III study
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2017)

Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment
por: Koiwa, Fumihiko, et al.
Publicado: (2018)

Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention
por: Goto, Shunsuke, et al.
Publicado: (2008)

First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants
por: Koiwa, Fumihiko, et al.
Publicado: (2022)

Clinical significance of parathyroid intervention on CKD-MBD management
por: Ogata, Hiroaki, et al.
Publicado: (2008)

En Bloc Cadaver Kidney Transplantation From a 9-Month-Old Donor to an Adult Recipient: Maturation of Glomerular Size and Podocyte in the Recipient
por: Hirukawa, Takashi, et al.
Publicado: (2017)

A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti‐Platelet Activation Membrane Dialyzer in Hemodialysis Patients
por: Kakuta, Takatoshi, et al.
Publicado: (2018)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Associations of calcium, phosphate and intact parathyroid hormone levels with mortality, residual kidney function and technical failure among patients on peritoneal dialysis
por: Murashima, Miho, et al.
Publicado: (2023)

Method comparison of Particle Enhanced Immunoturbidimetry (PEIT) with High Performance Liquid Chromatography (HPLC) for glycated hemoglobin (HbA1c) analysis
por: Dildar, Shabnam, et al.
Publicado: (2021)

Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia
por: Fukagawa, Masafumi, et al.
Publicado: (2008)

First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
por: Kazama, Junichiro James, et al.
Publicado: (2022)

Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study
por: Hasegawa, Takeshi, et al.
Publicado: (2018)

Disrupted tubular parathyroid hormone/parathyroid hormone receptor signaling and damaged tubular cell viability possibly trigger postsurgical kidney injury in patients with advanced hyperparathyroidism
por: Sato, Tetsuhiko, et al.
Publicado: (2019)

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
por: Tsuruya, Kazuhiko, et al.
Publicado: (2019)

Ultrasonographic Evaluation of Parathyroid Hyperplasia in Dialysis Patients
por: Pavlovic, Drasko, et al.
Publicado: (2006)

Long‐term outcomes of peritoneal dialysis catheters inserted by laparoscopic and percutaneous techniques in a single regional dialysis centre
por: Lee, Wai Gin, et al.
Publicado: (2022)

Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
por: Koiwa, Fumihiko, et al.
Publicado: (2016)

Glucocorticoid Receptor Antagonist Administration Prevents Adrenal Gland Atrophy in an ACTH-Independent Cushing's Syndrome Rat Model
por: Yasuda, Atsushi, et al.
Publicado: (2019)

Impact of timing of initiation of dialysis on long-term prognosis of patients undergoing hemodialysis
por: Zhang, Yumei, et al.
Publicado: (2018)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study
por: Inaguma, Daijo, et al.
Publicado: (2023)

Parathyroid carcinoma in a 13-year-old girl with a long-term survival
por: Omi, Yoko, et al.
Publicado: (2020)

Kidney Diseases Enhance Expression of Tetraspanin-8: A Possible Protective Effect against Tubular Injury
por: Hirukawa, Takashi, et al.
Publicado: (2014)

The association between parathyroid hormone and mortality in dialysis patients is modified by wasting
por: Drechsler, Christiane, et al.
Publicado: (2009)

Hungry bone syndrome in peritoneal dialysis patients after parathyroid surgery
por: Yeh, Heng, et al.
Publicado: (2023)

Long-term clinical outcomes of peritoneal dialysis patients: 9-year experience of a single centre in Turkey
por: TEKKARIŞMAZ, Nihan, et al.
Publicado: (2020)

Evaluation of ABCG2-mediated extra-renal urate excretion in hemodialysis patients
por: Ohashi, Yuki, et al.
Publicado: (2023)

Physical Activity and Blood Lipids and Lipoproteins in Dialysis Patients
por: Imamura, Hiroyuki, et al.
Publicado: (2012)

p-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress
por: Watanabe, Hiroshi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rf8k3k66rc1080ibsgu2h3463p